SMMT historical put/call options volume through April 2026, with the share price overlaid (right axis). Both puts and calls reached historic highs through 2024 and 2025 as ivonescimab moved through its pivotal trials. The options market is expressing a divided view of Summit’s near-term outcome: net bullish through most of the catalyst window, but with put volume sustained at multi-million-share levels indicating substantial hedging against the downside scenarios. The November 14, 2026 PDUFA decision is the single largest binary catalyst in the chart’s seven-year window.

On Tuesday, April 21, 2026, the London Gazette published a First Gazette Notice initiating the strike-off of Summit (Oxford) Limited, United Kingdom company number 04636431. The notice states that unless cause is shown to the contrary, the company will be struck off the register of Companies House and dissolved not less than two months from the publication date. On dissolution, all property and rights vested in the company, or held in trust for it, become bona vacantia and pass to the Crown.

For readers unfamiliar with UK corporate procedure, a First Gazette Notice is the initiating step in a compulsory strike-off. It is triggered when the Registrar of Companies has reasonable cause to believe the company is not carrying on business or is no longer in operation — most commonly evidenced by the company’s failure to file statutory returns such as the annual confirmation statement. The confirmation statement for Summit (Oxford) Limited was due January 25, 2026. The company did not file it. Eighty-two days later, on April 17, 2026, the U.S. parent company, Summit Therapeutics Inc., filed its definitive proxy statement on Form DEF 14A with the U.S. Securities and Exchange Commission, listing the UK office in Oxfordshire as a current leased property with a lease expiration in February 2027. Four days after that, the Gazette notice went live.

The UK entity now entering strike-off is the operational R&D subsidiary for Summit’s Oxfordshire office. It is subsidiary number four on the Exhibit 21.1 list that Summit filed with its Form 10-K on February 23, 2026 — two months before the Gazette notice, and 57 days before the proxy. The Exhibit 21.1 list comprises eight entities, and on the day the 10-K was signed by Summit’s three certifying officers, all eight were attested to exist as part of the consolidated group. One of those eight is now on the path to Crown-vested dissolution.

This article is the second in a sequence. On April 19, 2026, the Scientology Money Project published Truth Revealed: Billionaire OT8 Bob Duggan’s 4-Day Summit Therapeutics Engineered Financial Disclosures, which forecast the arrival of the Gazette notice before the notice was visible through any U.S. filing. The notice arrived on schedule.

This article takes the fact of its arrival and steps back to examine the architecture in which the strike-off is embedded: the eight-subsidiary, five-jurisdiction corporate structure Summit uses, the controlled-company governance framework that exempts it from standard Nasdaq oversight rules, and the accounting mechanism by which executives received an approximately $851 million compensation benefit during fiscal year 2025 without any performance gating.

The Oxford strike-off does not seem to be an isolated event. Rather, it appears to be the latest visible element of a consistent pattern of UK subsidiary wind-down, offshore entity deployment, and disclosure timing that Summit has followed since at least January 2023.

The Architecture in Summary

Summit Therapeutics’ corporate structure has four interlocking features. Each is disclosed in the 10-K or a related filing. Taken together, they describe a company that operates unusually even among late-stage clinical biotech firms with concentrated insider ownership.

First, one man — Robert W. Duggan — beneficially owns more than seventy percent of the company. This gives Summit formal “controlled company” status under Nasdaq listing rules, which exempts the company from three corporate governance requirements that apply to virtually every other Nasdaq issuer.

Second, the persons responsible for key operating and strategic decisions — the Chief Operating Decision Maker function under U.S. GAAP — are three: Duggan, his wife Mahkam Zanganeh (they married on December 18, 2024, a fact disclosed in the 10-K as a Risk Factor), and Manmeet Soni, the COO and CFO. Duggan and Zanganeh serve as Co-Chief Executive Officers.

Third, Summit consolidates eight subsidiaries across five jurisdictions: Delaware (two subsidiaries plus the Delaware parent), the Cayman Islands, England and Wales (three entities, one of which is now in Gazette strike-off), Switzerland, and Ireland. No operating facility is disclosed for either the Swiss or the Irish entity.

Fourth, during the second quarter of 2025, the Compensation Committee accelerated vesting on 44,488,976 performance-based stock options held by executives and certain employees, converting them from a performance-contingent grant into a time-vesting grant. The accounting consequence was a one-time $578 million charge through September 30, 2025, with $273 million more to be recognized over the following 1.6 years. Full-year 2025 stock-based compensation was $732.4 million, compared to $51.0 million in 2024 — a fourteenfold increase.

Each of these features is lawful. Each is disclosed. Nothing in this article is hidden. What this article does is gather the disclosures together, compare them against contemporaneous UK regulatory filings, and describe the architecture they jointly construct.

The Controlled-Company Exemption

Nasdaq Rule 5615(c)(1) defines a “controlled company” as an issuer of which more than fifty percent of the voting power for the election of directors is held by an individual, a group, or another company. A controlled company may elect exemptions from three corporate governance requirements that otherwise apply to Nasdaq-listed issuers: the requirement that a majority of the board of directors be independent; the requirement that the compensation committee be composed entirely of independent directors; and the requirement that director nominations be either selected by a majority of independent directors or by a nominating committee composed entirely of independent directors.

Summit’s 10-K addresses this directly. On page 66, in its Risk Factors section, the company states: “As of December 31, 2025, Mr. Duggan beneficially owned, in the aggregate, shares of common stock representing over 70% of our outstanding capital stock.” The same section provides the forward-looking position: “We have in the past, and we expect in the future, to rely on the ‘controlled company’ exemptions under the Nasdaq Stock Market listing requirements.”

The language is not ambiguous. Summit is asserting, as of the fiscal year most recently closed and with no announced intent to change, that it does not intend to comply with the board independence requirement, the compensation committee independence requirement, or the nominating committee independence requirement that otherwise apply to Nasdaq issuers. In the same 10-K, the company separately discloses that “a majority of the members of our board of directors were not independent directors, and our compensation and nominating and corporate governance committees did not consist entirely of independent directors.”

The practical consequence for stockholders is that the three governance mechanisms designed to check concentrated insider control — independent majority, independent compensation committee, independent nominating committee — have been formally waived. The board majority is not independent. The compensation committee is not entirely independent. The nominating committee is not entirely independent. The disclosure is unambiguous. What remains is the investor’s decision whether to treat the disclosure as a warning.

The Three-Person CODM

Under Accounting Standards Codification Topic 280, a public company is required to identify its Chief Operating Decision Maker — the person or persons responsible for allocating resources and assessing the performance of the enterprise — and to disclose the identity of that person or persons in the notes to the financial statements. In most companies with a single reportable segment, the CODM is a single person, typically the CEO.

Summit’s Q3 2025 Form 10-Q, filed October 20, 2025, describes the CODM as follows: “The Company’s chief operating decision makers (the ‘CODM function’), which are the Company’s Co-Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, and Chief Operating Officer and Chief Financial Officer, Mr. Soni, utilize consolidated net loss that is reported on the unaudited condensed consolidated statement of operations and comprehensive loss to make decisions about allocating resources and assessing performance for the entire Company.”

Three people. Duggan and Zanganeh as Co-Chief Executive Officers and therefore Co-Principal Executive Officers. Soni as Chief Operating Officer, Chief Financial Officer, and Director, and therefore Principal Financial Officer. The 10-K filed February 23, 2026 includes three separate Section 302 certifications under the Sarbanes-Oxley Act: Exhibit 31.1 signed by Duggan, Exhibit 31.2 signed by Zanganeh, and Exhibit 31.3 signed by Soni. A joint Section 906 certification, Exhibit 32.1, is signed by all three. All four exhibits carry the February 23, 2026 date.

The Co-CEO structure is itself unusual. According to academic and practitioner research on corporate governance, fewer than two percent of S&P 1500 companies operate with Co-CEOs in any given year. The arrangement is more common in small, founder-led firms than in publicly traded companies with multibillion-dollar market capitalizations. What makes Summit’s structure distinctive is not merely the Co-CEO arrangement but the combination: Co-CEOs who are married to each other, with a third person who is both COO and CFO and who signs the financial certification, all reporting to a board on which the majority is not independent, at a company of which one of the Co-CEOs beneficially owns more than seventy percent.

The 10-K discloses the marriage. On page 65, in the Risk Factors section under “Risks Related to Operations,” Summit states: “Mr. Duggan and Dr. Zanganeh have also been married since December 18, 2024.” This is the only disclosure of the marriage in the 10-K. It is flagged as a risk factor because the employment of both Co-CEOs is at-will, meaning either could terminate without notice, and the company does not maintain key person insurance on any of its executive officers.

The Eight Subsidiaries

Exhibit 21.1 to the 10-K, filed at a separate URL on the SEC EDGAR system, lists the subsidiaries of the registrant. For fiscal year 2025, the list comprises eight entities:

1. Summit Therapeutics Sub Inc. — Delaware, USA
2. Summit International Holdings Limited (Cayman Islands) — Cayman Islands
3. Summit Therapeutics Global LLC — Delaware, USA
4. Summit (Oxford) Limited — England and Wales
5. Summit Therapeutics Limited — England and Wales
6. Discuva Limited — England and Wales
7. Summit Therapeutics Swiss STS GmbH — Switzerland
8. Summit Therapeutics Ireland Limited — Ireland

The structure resolves into four layers. The domestic U.S. stack consists of the Delaware parent (Summit Therapeutics Inc., the registrant) and two Delaware operating entities (Summit Therapeutics Sub Inc. and Summit Therapeutics Global LLC). Beneath that sits a Cayman Islands holding company (Summit International Holdings Limited). Beneath the Cayman holdco sit three UK entities (Summit (Oxford) Limited, Summit Therapeutics Limited, and Discuva Limited) and two additional offshore operating entities (Summit Therapeutics Swiss STS GmbH and Summit Therapeutics Ireland Limited).

Each piece carries meaning that the 10-K text does not supply.

The Cayman Islands Entity

Summit International Holdings Limited is incorporated in the Cayman Islands. It is the second entity on the Exhibit 21.1 list, positioned between the two Delaware operating subsidiaries and the UK and European operating entities. Its function is not described in the 10-K. Cayman Islands holding companies, in the general pattern of U.S.-listed pharmaceutical companies, perform a limited set of structural roles: they hold intellectual property that can be licensed from a U.S. parent to foreign operating subsidiaries at arm’s-length royalty rates; they hold the equity of foreign operating subsidiaries and receive dividends from them; and they provide a tax-neutral venue for intercompany financing arrangements. The Cayman Islands levies no corporate income tax, no capital gains tax, no withholding tax on payments among corporate affiliates, and no stamp duty on share transfers among corporate entities. A Cayman holdco positioned between a U.S. parent and a set of foreign operating subsidiaries is, in accounting and legal terms, a tax and cash management vehicle.

Summit’s 10-K does not describe what Summit International Holdings Limited holds or what cash flows through it. The company has one licensed product candidate: ivonescimab. The patents in the Licensed Territory are in-licensed from Akeso, the Chinese biotech that developed ivonescimab. The U.S. parent is the party to the License Agreement with Akeso. The Cayman holdco’s role in relation to the License Agreement, if any, is not disclosed.

What is disclosed is that Summit’s Delaware operating subsidiaries (Summit Therapeutics Sub Inc. and Summit Therapeutics Global LLC) were formed after the 2020 U.S. redomiciliation transaction that moved the corporate parent from the United Kingdom to Delaware. The Cayman holdco appeared on the subsidiary list for the first time in the FY2023 Exhibit 21.1 filed February 2024. Its formation date is not in the 10-K. What the timing establishes is that Summit International Holdings Limited came into existence after the Akeso License Agreement closed in January 2023 and before the FY2023 10-K was filed in February 2024.

For readers familiar with cross-border pharmaceutical transactions, the presence of an undisclosed-function Cayman holdco in a structure that in-licenses intellectual property from a Chinese partner and pays milestone and royalty obligations back to that partner is a structure that rewards close reading. The Cayman Islands is one of the jurisdictions that the U.S. Treasury and the OECD have repeatedly flagged in base-erosion-and-profit-shifting (BEPS) analysis of pharmaceutical supply chains. Summit has not disclosed how the Cayman holdco interacts with the Akeso supply and royalty obligations. That disclosure, if it exists, is not in the 10-K.

The Three UK Entities and the January 17, 2023 Mass Dissolution

Of the three UK entities currently on Exhibit 21.1, two predate the 2020 U.S. redomiciliation and one was acquired earlier. Summit (Oxford) Limited — UK company number 04636431 — is the original operational R&D vehicle, continuous since 2003 under prior corporate names. It houses Summit’s only disclosed UK facility: 6,781 square feet at Milton Park, Oxfordshire, with a lease running to February 2027.

Summit Therapeutics Limited — originally Summit Therapeutics plc, the UK-listed public company predecessor — was converted to a UK private limited company at the time of the September 2020 redomiciliation, when Summit Therapeutics Inc. (a Delaware corporation) became the parent and registrant. Discuva Limited — UK company number 06169490 — was acquired by Summit in 2014 and is the entity that held the anti-infectives program built around ridinilazole. Summit sold the ridinilazole rights to Dr. Falk Pharma GmbH in 2020. Discuva has no disclosed active program in the FY2025 10-K.

The January 17, 2023 mass dissolution of six UK subsidiaries is the relevant historical anchor. Three days after the Akeso License Agreement closed in January 2023, Summit caused the simultaneous dissolution of six UK entities: Summit (Cambridge) Limited (formerly Daniolabs Limited), Summit (Wales) Limited (formerly Vastox Wales Limited), Summit Discovery 1 Limited (formerly Vastox Discovery 1 Limited), Summit Corporation Limited, Summit Infectious Diseases Limited, and Summit Corporation Employee Benefit Trust Company Limited. The dissolution wave occurred in the first week of the Akeso transaction and coincided with a complete pivot of Summit’s strategy from anti-infectives to oncology.

Against that historical backdrop, the April 21, 2026 Gazette notice for Summit (Oxford) Limited is the next episode in a continuing pattern, not an isolated event. The same vehicle through which Summit’s Oxford-based research staff has worked for more than two decades is now in the first Gazette stage of being extinguished. The 10-K makes no mention of this in its Subsequent Events discussion. The April 17, 2026 proxy describes the Oxford office as a current leased property. The April 21 Gazette confirms the underlying entity is on the path to Crown-vested dissolution.

The Swiss and Irish Entities

Summit Therapeutics Swiss STS GmbH and Summit Therapeutics Ireland Limited are new. Both appeared for the first time on the FY2024 Exhibit 21.1 filed February 24, 2025, meaning both were incorporated during calendar year 2024. Both remain on the FY2025 Exhibit 21.1 filed February 23, 2026. Neither has a disclosed physical facility in the 10-K’s Item 2 Properties table. Neither appears in the notes to the financial statements. Their operational purpose is undescribed.

Summit’s corporate website at smmttx.com complicates the picture. The public website lists Summit’s offices as Miami, Palo Alto, Princeton, Oxfordshire, and Dublin — with a Dublin address at 5 Harcourt Road, D02 FW64. The 10-K Item 2 Properties table lists Summit’s offices as Miami, Palo Alto, Princeton, Oxfordshire, and Menlo Park. Menlo Park appears in the SEC filing but not on the website. Dublin appears on the website but not in the SEC filing. The two five-city footprints do not reconcile, and the Dublin address — 5 Harcourt Road, D02 FW64 — corresponds to a serviced-office provider in central Dublin, not a purpose-built research facility.

Ireland and Switzerland are both recognized by the U.S. Treasury, the European Commission, and the OECD as jurisdictions with corporate tax rate structures that favor the location of intellectual property and intercompany licensing income. Ireland’s 12.5 percent corporate tax rate, combined with its longstanding “Double Irish” treatment and current Knowledge Development Box regime, has made Ireland a preferred destination for pharmaceutical intellectual property holding. Switzerland’s cantonal tax system, combined with patent box regimes introduced after the 2020 tax reform, provides similar treatment. Neither country’s presence on a biotech subsidiary list is unusual. What is unusual is the absence of any disclosed operational purpose for either entity in a company that, on every other disclosure page, describes itself as developing a single licensed product candidate with no other active programs.

Read together, the eight-subsidiary structure sketches an architecture:

A Delaware parent controlled by one individual at over seventy percent beneficial ownership.

Two Delaware operating subsidiaries.

A Cayman holdco of undescribed function.

Three UK entities, one of which is now entering dissolution, a second of which (Discuva Limited) has no active program, and a third of which (Summit Therapeutics Limited) is the vestigial remains of the former UK public company.

A Swiss GmbH with no disclosed facility.

An Irish Limited with no disclosed facility, whose Dublin address matches a serviced-office location. No employee count is disclosed by jurisdiction.

The 10-K reports 265 total employees, with 91 percent in the United States and 9 percent outside — approximately 24 employees distributed across the UK, Switzerland, and Ireland combined.

The 10-K Item 2 Properties table places the UK lease in Oxfordshire. The entity holding that lease is now being extinguished.

The Dublin, Swiss STS, and the other UK entities account for no disclosed facility at all.

The Type III Modification

During the second quarter of 2025, the Compensation Committee of Summit’s Board of Directors approved a modification to outstanding unvested performance-based stock option awards. Under the modification, “only the service-based vesting requirements” were required to continue to be satisfied for the options to vest. The performance-based vesting requirements — which would have required the achievement of regulatory or commercial milestones to trigger vesting — were removed.

The accounting treatment is disclosed in Note 11 to the Q3 10-Q. Because the modification converted awards that had been accounted for as improbable to vest (since the underlying performance conditions had not yet been satisfied) into awards that were now probable to vest (since only time and continued service were required), the change qualified as a Type III modification under Accounting Standards Codification Topic 718. A Type III modification requires the company to revalue the awards at the modification date and to recognize the new fair value as compensation expense over the remaining service period.

The numbers: 44,488,976 options were revalued on the modification date. Through September 30, 2025, the Company recognized $578,088 thousand — approximately $578 million — of expense associated with the modification. As of September 30, 2025, an additional $273,391 thousand — approximately $273 million — remained to be recognized over a weighted-average period of approximately 1.6 years. The total modification-related expense therefore approaches $851 million, recognized in the financial statements without any cash paid.

Because 2025 was a year in which Summit had no revenue and was using cash at approximately $322.9 million per year in operating activities, the stock-based compensation charge dominates the income statement.

Summit’s fiscal year 2025 net loss, as reported in the Form 10-K filed February 23, 2026, was $1,079.6 million — approximately $1.08 billion, or over one billion dollars, up from $221.3 million in 2024.

Of the 2025 loss, $537.7 million was Research and Development expense (including $218.6 million in stock-based compensation) and $556.7 million was General and Administrative expense (including $513.8 million in stock-based compensation).

The year-over-year increase in G&A was approximately 9.2 times. Almost the entire increase was stock-based compensation arising from the Type III modification.

The question a reader of the 10-K may ask is what decisions the Compensation Committee considered before approving the modification. The 10-K does not disclose the deliberations. The Compensation Committee is not required to be composed entirely of independent directors, because Summit has elected the controlled-company exemption. The beneficiary class of the modification included executives who are themselves members of the board or who report to a board on which the majority is not independent. The Compensation Committee approved the acceleration; the Board of Directors’ composition allowed the Compensation Committee to do so without independent-majority oversight; and Duggan, as beneficial owner of more than seventy percent of the shares and as one of the two Co-CEOs, was among the persons whose interests were affected by the decision.

Nothing about this sequence is illegal. It is all disclosed. It is a consequence of the controlled-company exemption operating in combination with the Co-CEO structure and the Type III modification. What it describes is a mechanism by which executives received an approximately $851 million compensation benefit — net of valuation adjustments and vesting mechanics — for which neither a performance milestone nor board independence nor stockholder approval was required at the time of the decision.

The Related-Party Network

The 10-K discloses an interlocking web of related-party arrangements. Each is individually modest. In combination they describe the ordinary commercial flows through which the three-person CODM function is also an interlocking set of counterparties to the company.

The MZA sublease. Summit’s Menlo Park office space is subleased from Maky Zanganeh and Associates, Inc., owned by Zanganeh. Three amendments between 2022 and 2024 brought the total office footprint to 5,922 square feet, and brought Summit’s proportionate share of the MZA master-lease obligation to 93.6 percent. Summit paid MZA $173 thousand during the first nine months of 2025 under the sublease.

The Miami subleases. Effective April 1, 2024, Summit entered into two sublease agreements at its Miami headquarters. Genius 24C Inc. — an affiliate of Duggan — sublet 848 square feet for a 62-month term at approximately $446 thousand total rent. Duggan Investments Research LLC — also an affiliate of Duggan — sublet another 848 square feet for a 62-month term at another approximately $446 thousand. Summit collected $140 thousand of sublease income from these two entities over the first nine months of 2025, a direct revenue stream from Duggan-controlled entities to Summit at Summit’s Miami headquarters.

The Akeso relationship. Summit’s license agreement with Akeso, Inc., the Chinese biotech company from which Summit in-licensed ivonescimab, includes a board seat. Akeso’s founder, Dr. Yu (Michelle) Xia, sits on Summit’s board of directors pursuant to the terms of the License Agreement. Summit paid Akeso $28,628 thousand in clinical services fees during the first nine months of 2025.

The Wilson Sonsini relationship. Kenneth A. Clark, a member of Summit’s board of directors, is a partner at Wilson Sonsini Goodrich & Rosati P.C., the outside law firm engaged by Summit. Summit paid Wilson Sonsini approximately $1.4 million during the first nine months of 2025 for legal services rendered.

The September 2024 PIPE. On September 11, 2024, Summit closed a $235 million private placement at $22.70 per share. All Section 16 officers participated. Duggan purchased 3,325,991 shares for $75.5 million. Zanganeh purchased 44,052 shares for $1 million. Soni purchased 44,052 shares for $1 million. Director Jeff Huber, through his controlled entity Caspian Capital LLC, purchased 44,052 shares for $1 million. The Chief Accounting Officer also participated. Of the $235 million raised, approximately $79 million came from Section 16 officers and the Huber-controlled entity.

The Duggan warrants. In March 2025, Duggan exercised 2,936,221 of 3,985,055 warrants received in a December 24, 2019 private placement at an exercise price of $1.58. On April 8, 2025, he exercised the remaining 1,048,834 warrants at the same price. The warrants had been issued at terms set in late 2019, when Summit was a microcap. By March and April 2025, Summit’s stock was trading between $18 and $24 per share. The exercise economics produced substantial unrealized gains realized as stock rather than cash, the exact magnitude depending on the share price on each exercise date. Summit received $7.3 million in cash proceeds from the warrant exercises.

The December 2022 Notes. Separately from the ordinary-course relationships above, in December 2022, Summit entered into a Note Purchase Agreement under which Duggan and Zanganeh loaned Summit a combined $520 million in unsecured promissory notes: $400 million from Duggan due February 15, 2023; $20 million from Zanganeh due February 15, 2023; and $100 million from Duggan due September 15, 2023. The notes carried 7.5 percent interest through February 15, 2023, with prepaid interest paid in Summit shares at a price of $0.7913 per share — 9,720,291 shares total.

After February 15, 2023, the notes accrued interest at the U.S. prime rate plus 50 basis points for three months, then the U.S. prime rate plus 300 basis points. In February 2024, the remaining Duggan note was amended to accrue interest at the greater of 12 percent or the U.S. prime rate plus 350 basis points. The notes have all been repaid, the last repayment occurring October 1, 2024.

But on March 17, 2025, the Rainaldi Revocable Trust, a Summit stockholder, filed a derivative lawsuit in the Delaware Court of Chancery against Summit’s current and former directors, alleging breach of fiduciary duty and unjust enrichment in the issuance and administration of the December 2022 Notes.

The suit seeks, among other remedies, rescission of the shares that Duggan and Zanganeh received as part of the prepaid interest payments — the 9,720,291 shares issued at $0.7913 per share. The Motion to Dismiss was filed May 16, 2025. On May 29, 2025, the plaintiff filed a motion to certify constitutional questions to the Delaware Supreme Court. On June 18, 2025, the Court granted a stipulation staying briefing on both motions pending the Delaware Supreme Court’s decision in a parallel case. The litigation is pending.

What the 10-K Says and What It Does Not Say

The 10-K discloses all of the above. The text cited in this article is drawn from the filing itself, from the Q3 2025 10-Q, from Exhibit 21.1, and from the four Sarbanes-Oxley certifications filed as separate exhibits on February 23, 2026. The disclosures are clear, voluntary under securities law, and filed with the Securities and Exchange Commission in the ordinary course.

What the 10-K does not disclose:

It does not disclose the business purpose of Summit International Holdings Limited, the Cayman Islands holdco positioned between the Delaware operating subsidiaries and the foreign operating entities. The 10-K does not describe what assets the Cayman holdco holds, what cash flows through it, or what its role is in the Akeso License Agreement and supply chain.

It does not disclose the business purpose of Summit Therapeutics Swiss STS GmbH. The entity appears on the Exhibit 21.1 list. It has no disclosed facility, no disclosed employees, and no mention in the 10-K’s Item 2 Properties table. Its incorporation date is not in the 10-K. Its functional role within the consolidated group is not described.

It does not disclose the business purpose of Summit Therapeutics Ireland Limited. The entity appears on Exhibit 21.1. The company’s public website lists a Dublin address at 5 Harcourt Road. The 10-K does not include Dublin in its Item 2 Properties table.

It does not disclose the deliberations of the Compensation Committee that led to the Q2 2025 Type III modification. The 10-K discloses only that the Compensation Committee approved the modification, that employee consent was required, and that the mechanical consequence was to convert 44,488,976 performance-based options to service-based vesting.

It does not disclose whether the Type III modification was reviewed by any independent committee or by any stockholder vote. Because Summit is a controlled company, no such review was required. The 10-K does not affirm that one took place.

It does not reconcile the five-city footprint in Item 2 Properties (Miami, Palo Alto, Princeton, Oxfordshire, Menlo Park) with the five-city footprint on smmttx.com (Miami, Palo Alto, Princeton, Oxfordshire, Dublin). Menlo Park is in the SEC filing but not on the website. Dublin is on the website but not in the SEC filing.

It does not disclose that Summit (Oxford) Limited, one of the eight entities on its Exhibit 21.1 list, had failed to file its statutory confirmation statement by the January 25, 2026 deadline, and that by the time the 10-K was signed on February 23, 2026, the entity was 29 days overdue.

What Happens Before November 14

The architecture described in this article is the architecture that exists today, as disclosed on February 23, 2026 (the 10-K), April 17, 2026 (the definitive proxy statement), and April 21, 2026 (the London Gazette). It is the architecture within which the November 14, 2026 PDUFA decision on ivonescimab will be made. If the FDA approves ivonescimab for the proposed second-line EGFR-mutated NSCLC indication, Summit will transition from a development-stage company to a commercial-stage company for the first time in its corporate history. The milestone payments to Akeso — up to $1.05 billion in regulatory milestones and up to $3.51 billion in commercial milestones, plus low-double-digit royalties — will begin to come due. The Type III modification options — held by executives who now have no performance gating on their vesting — will continue to vest on a time-only basis through mid-to-late 2027.

The 10-K does not describe how approval will alter the architecture. It does not disclose any plan to exit controlled-company status. It does not disclose any plan to appoint a majority-independent board. It does not disclose any plan to separate the Co-CEO structure. What it does disclose is that Summit expects, on a forward-looking basis, to continue relying on the controlled-company exemption.

What the April 21, 2026 Gazette notice adds to that forward view is a signal that the UK operational layer is being wound down even as U.S. regulatory filings describe it as continuing. The confirmation statement for Summit (Oxford) Limited was 86 days overdue on the day the Gazette notice was published. It was 29 days overdue on the day the 10-K was signed. It was 82 days overdue on the day the DEF 14A proxy was filed. Summit Therapeutics Inc. is the parent of Summit (Oxford) Limited. Summit Therapeutics Inc.’s certifying officers — Duggan, Zanganeh, and Soni — are also, in their corporate capacity, the persons responsible for ensuring that UK subsidiary statutory filings are made on time. The confirmation statement was not made on time. The consequence, now visible through the London Gazette, is the beginning of dissolution proceedings.

The two-month objection window that follows the First Gazette Notice will run until approximately June 21, 2026 — five months before the PDUFA date. Between now and June 21, Summit has the opportunity, if it chooses, to cause Summit (Oxford) Limited to file the overdue confirmation statement and request the Registrar to withdraw the strike-off. It also has the option to do nothing and allow dissolution to proceed. Neither option has yet been disclosed by Summit Therapeutics Inc. in any SEC filing.

For stockholders, the pattern now visible is not a single event. It is the continuation of a pattern. January 17, 2023: six UK subsidiaries dissolved simultaneously, three days after the Akeso License Agreement closed. 2024: Swiss and Irish entities added to the subsidiary list with no disclosed operational purpose. Q2 2025: Type III modification approved by a compensation committee that is not entirely independent, under the controlled-company exemption. February 23, 2026: 10-K filed, with the Oxford subsidiary confirmation statement already 29 days overdue and no disclosure of that fact. April 17, 2026: proxy statement filed, with the Oxford subsidiary confirmation statement then 82 days overdue and no disclosure of that fact. April 21, 2026: First Gazette Notice published, making the overdue filing and pending dissolution public through a UK regulatory channel that U.S. investors would generally not encounter through their SEC research.

The four-day window between the April 17 proxy and the April 21 Gazette notice is the feature of the architecture that this article and its predecessor have pursued. The Gazette notice has now arrived. The architecture remains in place.

The London Gazette Strike Off Notice of April 21, 2026:

Summit Therapeutics SEC Form 10-K for 2025 details the risks the company faces in its disclosure, particularly given its ties to its Chinese partner Akeso: 

Risks Related to Our Financial Position and Need for Additional Capital
• We are a development-stage company and have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for at least the next several years and may never generate profits from operations or maintain profitability.
• We have not yet demonstrated an ability to successfully complete development of any product candidates, and a Biologics License Application (“BLA”) that has been accepted for filing, such as the BLA relating to the HARMONi study, may not ultimately lead to regulatory approval and commercialization of ivonescimab.
• We will need substantial additional capital to fund our operations. Raising additional capital may cause dilution to our investors or restrict our operations.
• We depend heavily on the success of ivonescimab. If we are unable to successfully develop and commercialize ivonescimab, or experience significant delays in doing so, we may extend the period in which we will incur significant financial losses as an organization.
• Worldwide economic, social and geopolitical instability could adversely affect our business and ability to raise capital in the future.

Sources

All material in this article is drawn from primary-source filings with the U.S. Securities and Exchange Commission and with UK Companies House. The primary sources are:

Summit Therapeutics Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed February 23, 2026, SEC Accession No. 0001599298-26-000015, at https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000015/smmt-20251231.htm

Exhibit 21.1 (Subsidiaries of the Registrant) to the 10-K, at https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000015/sum-ex211_20251231xxsubsid.htm

Exhibits 31.1, 31.2, 31.3 (SOX 302 certifications signed by Duggan, Zanganeh, and Soni respectively) and Exhibit 32.1 (joint SOX 906 certification), all dated February 23, 2026.

Summit Therapeutics Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed October 20, 2025.

Summit Therapeutics Inc. Definitive Proxy Statement on Schedule 14A, filed April 17, 2026.

Summit Therapeutics Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed February 24, 2025, SEC Accession No. 0001599298-25-000048, with FY2024 Exhibit 21.1.

Prior-year Exhibit 21.1 filings: FY2023 (SEC Accession No. 0001599298-24-000031) and FY2022 (SEC Accession No. 0001599298-23-000034).

The London Gazette, First Gazette Notice 04636431 for Summit (Oxford) Limited, publication date April 21, 2026.

Rainaldi Revocable Trust, Derivative Complaint, Delaware Court of Chancery, filed March 17, 2025 (as described in the 10-K, Item 3, Legal Proceedings).

Truth Revealed: Billionaire OT8 Bob Duggan’s 4-Day Summit Therapeutics Engineered Financial Disclosures,” The Scientology Money Project, April 19, 2026.